Investigating the role of early low-dose aspirin in diabetes: A phase III multicentre double-blinded placebo-controlled randomised trial of aspirin therapy initiated in the first trimester of diabetes pregnancy

Simple item page
dc.contributor.authorFinnegan, Catherine
dc.contributor.authorDicker, Patrick
dc.contributor.authorFernandez, Elena
dc.contributor.authorTully, Elizabeth
dc.contributor.authorHiggins, Mary
dc.contributor.authorDaly, Sean
dc.contributor.authorRiordan, Mairead O’
dc.contributor.authorDunne, Fidelma P.
dc.contributor.authorGaffney, Geraldine
dc.contributor.authorSlevin, John
dc.contributor.authorCiprike, Vinete
dc.contributor.authorBreathnach, Fionnuala
dc.contributor.funderHealth Research Boarden
dc.date.accessioned2019-12-04T11:25:29Z
dc.date.available2019-12-04T11:25:29Z
dc.date.issued2019-10-15
dc.description.abstractBackground: Preeclampsia, preterm birth and low birth weight represent key contributing factors to perinatal morbidity and mortality. Pregnancies complicated by type 1 and type 2 diabetes are at increased risk of these complications, which are purported to be largely attributed to placental dysfunction. Studies investigating a potential role for aspirin therapy in optimizing perinatal outcome have consistently failed to demonstrate a benefit among women with pre-existing diabetes, and yet widespread aspirin administration has become common practice in many centres. This study seeks to examine the effect of aspirin therapy, administered from the first trimester until 36 weeks gestation, on perinatal outcome in women with established pre-pregnancy diabetes. Our hypothesis is that aspirin therapy will reduce complications mediated by placental dysfunction, and improve perinatal outcomes. Methods: This phase III double-blinded, placebo-controlled randomized clinical trial will be conducted in seven tertiary-level perinatology centres in Ireland. Consenting participants who meet all eligibility criteria will be allocated randomly to either aspirin 150 mg once daily or matching placebo, commenced between 11 + 0 and 13 + 6 weeks. Allocation will take place electronically using software by Clininfo with randomization tables provided by the trial biostatistician. The primary outcome will be a composite clinical measure of placental dysfunction (preeclampsia, preterm birth before 34 weeks, birthweight below the 10th centile or perinatal mortality). This trial has been set up such that it is parallel in design and is a superiority study. No participants have been recruited yet. The trial has been registered with Eudra Clinical Trials - EudraCT Number 2018-000770-29. Funding for this trial was granted by the Health research Board (HRB) 1/9/2017(DIFA-2017-026). Discussion: Aspirin therapy has been investigated for the prevention of preeclampsia owing to its reduction on thromboxane production. Previous studies have failed to demonstrate a beneficial effect of aspirin on perinatal outcome amongst women with type I or type II diabetes. It is plausible that the failure to observe benefit to date, among the limited aspirin studies that have included participants with diabetes, may be a consequence of aspirin initiation too late in pregnancy to exert any effect on placentation. We believe that if aspirin is to be used for the prevention of placental dysfunction, it must be initiated before the second active phase of trophoblast invasion, which takes place from 14 weeks’ gestation onwards. No randomized trials investigating the role of aspirin in prevention of preeclampsia in pregnancies complicated by diabetes have previously initiated treatment in the first trimester, the gestational period at which it is most likely to exert an effect on placentation.en
dc.description.sponsorshipHealth research Board (1/9/2017(DIFA-2017-026)en
dc.description.statusPeer revieweden
dc.description.versionPublished Versionen
dc.format.mimetypeapplication/pdfen
dc.identifier.articleid100465en
dc.identifier.citationFinnegan, C., Dicker, P., Fernandez, E., Tully, E., Higgins, M., Daly, S., Riordan, M. O., Dunne, F., Gaffney, G., Slevin, J., Ciprike, V. and Breathnach, F. (2019) 'Investigating the role of early low-dose aspirin in diabetes: A phase III multicentre double-blinded placebo-controlled randomised trial of aspirin therapy initiated in the first trimester of diabetes pregnancy', Contemporary Clinical Trials Communications, 16, 100465. (6pp.) doi: 10.1016/j.conctc.2019.100465en
dc.identifier.doi10.1016/j.conctc.2019.100465en
dc.identifier.eissn2451-8654
dc.identifier.endpage6en
dc.identifier.journaltitleContemporary Clinical Trials Communicationsen
dc.identifier.startpage1en
dc.identifier.urihttps://hdl.handle.net/10468/9318
dc.identifier.volume16en
dc.language.isoenen
dc.publisherElsevier Incen
dc.rights©2019 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)en
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/en
dc.subjectAspirinen
dc.subjectPregnancyen
dc.subjectDiabetesen
dc.subjectpre-eclampsiPen
dc.titleInvestigating the role of early low-dose aspirin in diabetes: A phase III multicentre double-blinded placebo-controlled randomised trial of aspirin therapy initiated in the first trimester of diabetes pregnancyen
dc.typeArticle (peer-reviewed)en
Files
Original bundle
Now showing 1 - 2 of 2
Thumbnail Image
Name:
1-s2.0-S2451865419302273-main.pdf
Size:
341.59 KB
Format:
Adobe Portable Document Format
Description:
Published version
Download
Thumbnail Image
Name:
1-s2.0-S2451865419302273-mmc1.docx
Size:
48.75 KB
Format:
Microsoft Word XML
Description:
Supplementary file 1
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
2.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Obstetrics & Gynaecology - Journal articles